Literature DB >> 2009315

Cell cycle related studies on thymidine kinase and its isoenzymes in Ehrlich ascites tumours.

Q He1, S Skog, B Tribukait.   

Abstract

Thymidine kinase (TK) activity was measured in relation to the cell cycle of in vivo growing ascites tumour cells. The cells were synchronized by means of centrifugal elutriation and the cell cycle composition of the cell fractions was determined by flow cytometry. TK activity was low in G1, increased during S phase and declined in G2. A half-life of TK activity of about 45 min was found throughout the cell cycle. Four isoenzymes at pI values of 4.1, 5.3, 6.9 and 8.3, denoted as isoenzymes 1-4, were identified using isoelectric focusing. Isoenzymes 3 and 4 were responsible for the profound cell cycle related changes in the TK activity. Corresponding isoenzymes were also found in the fetal mouse liver. In the adult mouse liver isoenzyme 2 was the dominating isoenzyme. The half-life of the isoenzymes was in the same range as for the total TK activity. We conclude that the low TK activity in G1 is due to degradation of the enzyme in G2 at a normal rate combined with an arrest in the synthesis of TK. We also conclude that isoenzyme 4 and the intermediate isoenzyme 3, which had earlier been suggested to be a mitochondrial form of TK, in fact represent cytoplasmatic forms of TK. According to cell cycle and pI studies, isoenzyme 2 belongs to the mitochondrial form. Studies with various phosphor donors and specific substrates, however, indicate that it also contains a cytoplasmic component.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2009315     DOI: 10.1111/j.1365-2184.1991.tb01506.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  7 in total

1.  Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.

Authors:  Yan Chen; Mingang Ying; YanSong Chen; Minhua Hu; Yingying Lin; Dedong Chen; Xiaoli Li; Ming Zhang; Xia Yun; Ji Zhou; Ellen He; Sven Skog
Journal:  Int J Clin Oncol       Date:  2010-04-01       Impact factor: 3.402

2.  Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort.

Authors:  Rohina Rubicz; Shanshan Zhao; Craig April; Jonathan L Wright; Suzanne Kolb; Ilsa Coleman; Daniel W Lin; Peter S Nelson; Elaine A Ostrander; Ziding Feng; Jian-Bing Fan; Janet L Stanford
Journal:  Prostate       Date:  2015-05-18       Impact factor: 4.104

3.  X-irradiation effects on thymidine kinase (TK): I. TK1 and 2 in normal and malignant cells.

Authors:  Q He; S Skog; I Welander; B Tribukait
Journal:  Cell Prolif       Date:  2002-04       Impact factor: 6.831

4.  Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.

Authors:  Kiran Kumar Jagarlamudi; Lars Olof Hansson; Staffan Eriksson
Journal:  BMC Cancer       Date:  2015-02-18       Impact factor: 4.430

5.  Whole genome sequencing of matched tumor, adjacent non-tumor tissues and corresponding normal blood samples of hepatocellular carcinoma patients revealed dynamic changes of the mutations profiles during hepatocarcinogenesis.

Authors:  Ruifang Mao; Jie Liu; Guanfeng Liu; Shanshan Jin; Qingzhong Xue; Liang Ma; Yan Fu; Na Zhao; Jinliang Xing; Lanjuan Li; Yunqing Qiu; Biaoyang Lin
Journal:  Oncotarget       Date:  2017-04-18

6.  Analytical and clinical characterization of an optimized dual monoclonal sandwich ELISA for the quantification of thymidine kinase 1 (TK1) protein in human blood samples.

Authors:  K K Jagarlamudi; Swinkels L; Zupan M; Osredkar J; Venge P; Eriksson S
Journal:  PLoS One       Date:  2022-10-06       Impact factor: 3.752

7.  Quaternary structures of recombinant, cellular, and serum forms of thymidine kinase 1 from dogs and humans.

Authors:  Sharif Hanan; Kiran Kumar Jagarlamudi; Wang Liya; He Ellen; Eriksson Staffan
Journal:  BMC Biochem       Date:  2012-06-28       Impact factor: 4.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.